Skip to main content
Premium Trial:

Request an Annual Quote

ProMetic Sells $3.4M Worth of Synthetic Ligands to Undisclosed Customer

NEW YORK (GenomeWeb News) — ProMetic BioSciences has sold CA$3.9 million ($3.4 million) worth of its mimetic ligand affinity adsorbent product to an “existing multinational” client, the company said today.
 
ProMetic Bio, a division of ProMetic Life Sciences, said it will supply the products in the first and second quarters of 2007.
 
Earlier this month, ProMetic said it would develop synthetic ligands for Novartis' vaccine program.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.